浙江医药筹划控股子公司分拆赴港上市

Group 1 - Zhejiang Pharmaceutical plans to spin off its subsidiary, Zhejiang Xima Biotechnology Co., Ltd., for a listing on the Hong Kong Stock Exchange [1] - The spin-off aims to enhance the development of the biopharmaceutical sector, broaden financing channels, and improve overall profitability and core competitiveness of Zhejiang Pharmaceutical [1] - The spin-off will not result in Zhejiang Pharmaceutical losing control over Xima Biotechnology and will not adversely affect other business segments or the company's overall profitability [1] Group 2 - Xima Biotechnology focuses on the research and production of biopharmaceuticals and is the R&D mainstay of Zhejiang Pharmaceutical's biopharmaceutical sector [2] - In early November, Xima Biotechnology completed a strategic acquisition of all preclinical pipelines and corresponding platform technology patents from Shanghai New Concept Biotechnology Co., Ltd., enhancing its R&D capabilities [2] - The acquisition brought in Dr. Han Nian, a scientist with nearly 30 years of experience in the biopharmaceutical industry, to serve as Chief Scientific Officer, strengthening Xima Biotechnology's expertise in drug development [2]